For example, in colorectal cancer, BRAF mutations are mutually exclusive with mutations in KRAS [65], indicating that a single alteration of the activity of a pathway member is sufficient to induce misregulation of that pathway. This evidence concerns the gene KRAS and colorectal cancer.